No Detail Found!

Role of intravitreal bevacizumab (Avastin) in the treatment of clinically significant macular edema.

Author(s)
Furqan Ahmed Khan
Mahmood Ali
Sarah Zafar
Abstract
Purpose: To determine efficacy of single intravitreal injection of bevacizumab (Avastin) for treatment of clinically significant macular edema (CSME). Participants and methods: A quasi experimental month study was carried out at the retina clinic of Al Shifa Trust Eye Hospital, Rawalpindi from 1st January 2010 to 31st December 2010. A total 107 patients with CSME were included in this study. All patients were evaluated for visual acuity, anterior and posterior segment while central macular thickness was documented through optical coherence tomography. A single injection of bevacizumab was administered in all the patients. Outcome measures (improvement in BCVA and decrease in central retinal thickness) were evaluated at 2weeks, 1 month and 2 months. Results: All except one patient completed 2 months of follow-up. At baseline mean BCVA ±SD was 0.967591±0.3705 logMAR of Snellen letters, which significantly improved to 0.808525±0.3260 at 2 weeks, 0.65581±0.36078 at 1 month, and 0.6319±0.3900 at 2 months (for each, p-value
Publication Details
Page(s) 88-93
DOI DOI not available
Published Journal: Al-Shifa journal of Opthalmology, Volume: 7, Issue: 2, Year: 2011

Request the full text from PASTIC

0

Citations

0

Downloads

38

Views